Angiex, Inc.
Nuclear-Delivered Antibody-Drug Conjugate therapeutics for cancer
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2015
- Latest Form D
- $11M, Aug 2025
- Total capital
- $13.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $13.9M
- 2 Form D · last Aug 2025
- 14 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 31 pending · first 2021
- Rank in peer group#339 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$11M
- Private capital raisedForm D · SEC · 1st filing$2.9M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#339 · top 23%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Paul JaminetResearcherExecutive Officer, DirectorLinked by 2 patents
- Amal AminDirectorNamed in SEC Form D filings
- Errik AndersonDirectorNamed in SEC Form D filings
- Fabian HansenDirectorNamed in SEC Form D filings
- Haijing GuoDirectorNamed in SEC Form D filings
- Iain DukesDirectorNamed in SEC Form D filings
Show all 9 people
- Jason CammDirectorNamed in SEC Form D filings
- Jonathan AdamsDirectorNamed in SEC Form D filings
- Tina NeelDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 34- GrantedAntibody-oligonucleotide ConjugatesUSPTOUS 12,458,705
- GrantedAntibody-drug Conjugates Comprising ANTI-TM4SF1 Antibodies And Methods Of Using The SameUSPTOUS 12,428,477
- PendingANTI-TM4SF1 Antibody-drug Conjugates Comprising Cleavable Linkers And Methods Of Using SameUSPTOApplication 18971926
Show all 34 patent records
- Antibody-oligonucleotide ConjugatesNov 4, 2025 · US 12,458,705Granted
- Antibody-drug Conjugates Comprising ANTI-TM4SF1 Antibodies And Methods Of Using The SameSep 30, 2025 · US 12,428,477Granted
- ANTI-TM4SF1 Antibody-drug Conjugates Comprising Cleavable Linkers And Methods Of Using SameMay 15, 2025 · Application 18971926Pending
- Degrader-antibody Conjugates And Methods Of Using SameOct 17, 2024 · Application 18617021Pending
- Combinations Comprising ANTI-TM4SF1 Antibodies And Immunotherapeutic Agents And Methods Of Using The SameMay 23, 2024 · Application 18473511Pending
- Maytansine-antibody Conjugates And Methods Of Using SameMay 16, 2024 · Application 18473517Pending
- Antimitotic Tetrapeptide-antibody Conjugates And Methods Of Using SameNov 23, 2023 · Application 18171909Pending
- ANTI-TM4SF1 Antibody-drug Conjugates Comprising Cleavable Linkers And Methods Of Using SameOct 26, 2023 · Application 18161405Pending
- ANTI-TM4SF1 Antibody Drug Conjugates And Methods Of Using SameSep 21, 2023 · Application 18051573Pending
- ANTI-TM4SF1 Antibodies And Methods Of Using SameAug 25, 2022 · Application 17532660Pending
- ANTI-TM4SF1 Antibodies And Methods Of Using SameMay 19, 2022 · Application 17532664Pending
- ANTI-TM4SF1 Antibodies And Methods Of Using SameDec 28, 2021 · US 11,208,495Granted
- Antimitotic Tetrapeptide-antibody Conjugates And Methods Of Using SameApplication 63070568Pending
- ANTI-TM4SF1 Antibody-drug Conjugates Comprising Cleavable Linkers And Methods Of Using SameApplication 63059459Pending
- Degrader-antibody Conjugates And Methods Of Using SameApplication 63044699Pending
- Antibody-oligonucleotide ConjugatesApplication 62684131Pending
- ANTI-TM4SF1 Antibody Drug Conjugates And Methods Of Using SameApplication 63019026Pending
- Degrader-antibody Conjugates And Methods Of Using SameApplication 63000991Pending
- Antibody-drug Conjugates Comprising ANTI-TM4SF1 Antibodies And Methods Of Using The SameApplication PCTUS2020020207Pending
- Antibody-oligonucleotide ConjugatesApplication PCTUS2019036836Pending
- Antibody-drug Conjugates Comprising ANTI-TM4SF1 Antibodies And Methods Of Using SameApplication 62811411Pending
- ANTI-TM4SF1 Antibodies And Methods Of Using SameApplication PCTUS2018048402Pending
- ANTI-TM4SF1 Antibodies And Methods Of Using SameApplication 62550994Pending
- ANTI-TM4SF1 Antibody-drug Conjugates Comprising Cleavable Linkers And Methods Of Using SameApplication PCTUS2023024732Pending
- Degrader-antibody Conjugates And Methods Of Using SameApplication PCTUS2022045467Pending
- Maytansine-antibody Conjugates And Methods Of Using SameApplication PCTUS2022022041Pending
- Combinations Comprising ANTI-TM4SF1 Antibodies And Immunotherapeutic Agents And Methods Of Using The SameApplication PCTUS2022022035Pending
- Degrader-antibody Conjugates And Methods Of Using SameApplication 63250722Pending
- Antimitotic Tetrapeptide-antibody Conjugates And Methods Of Using SameApplication PCTUS2021047609Pending
- ANTI-TM4SF1 Antibody-drug Conjugates Comprising Cleavable Linkers And Methods Of Using SameApplication PCTUS2021044046Pending
- ANTI-TM4SF1 Antibody Drug Conjugates And Methods Of Using SameApplication PCTUS2021030226Pending
- Degrader-antibody Conjugates And Methods Of Using SameApplication PCTUS2021024535Pending
- Maytansine-antibody Conjugates And Methods Of Using SameApplication 63166793Pending
- Combinations Comprising ANTI-TM4SF1 Antibodies And Immunotherapeutic Agents And Methods Of Using The SameApplication 63166805Pending
Related companies, and why
- Carbon BiosciencesSimilar federal contract value in Biotech · null in contracts
- Hoth Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Cristcot LLCSimilar federal contract value in Biotech · null in contracts
- SpringWorks TherapeuticsSimilar federal contract value in Biotech · null in contracts
- ALAMAB THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- Alkahest, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .